Navigation Links
Onyx Pharmaceuticals Reports First Quarter 2011 Financial Results
Date:5/4/2011

tible senior notes due 20162,4352,157Advance funding to S*BIO12,666-Impairment of equity investment in S*BIO3,000-Non-GAAP net loss (5)$(14,211)$  (1,497)Computation of non-GAAP diluted net lossNon-GAAP net loss (5)$(14,211)$  (1,497)Add:Interest and issuance costs related to dilutive convertible senior notes (6)--Non-GAAP net loss - diluted (5)$(14,211)$  (1,497)Computation of non-GAAP diluted sharesBasic shares63,00862,353Dilutive effect of convertible senior notes (6)--Non-GAAP diluted shares (5)63,00862,353Non-GAAP net loss per share (5)$
(0.23)$
(0.02)Non-GAAP net loss per share - diluted (5) $
(0.23)$
(0.02)(5)
This press release includes the following non-GAAP financial measures: non-GAAP net loss, non-GAAP net loss – diluted, non-GAAP net loss per share, and non-GAAP net loss per share – diluted. The foregoing table reconciles these non-GAAP measures to the most comparable financial measures calculated in accordance with GAAP.Onyx management uses these non-GAAP financial measures to monitor and evaluate our operating results and trends on an on-going basis and internally for operating, budgeting and financial planning purposes. Onyx management believes the non-GAAP information is useful for investors by offering them the ability to better identify trends in our business and better understand how management evaluates the business. These non-GAAP measures have limitations, however, because they do not include all items of income and expense that affect Onyx. These non-GAAP financial measures that management uses are not prepared in accordance with, and should not be considered in isolation of, or an as alternative to, measurements required by GAAP.These non-GAAP financial measures exclude the following items from GAAP net loss and diluted per share amounts:Contingent consideration expense
: The effects of contingent consideration expense are excluded due to the nature of this charge,
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... 2014  Dompe, a leader in R&D for new therapeutic ... (Recombinant Human Nerve Growth Factor) has been designated as an ... The candidate drug, developed by the research ... the treatment of neurotrophic keratitis, a degenerative corneal disease that ... is currently without a cure. This is the second orphan ...
(Date:7/23/2014)... 23, 2014  ArmaGen, a privately held biotechnology ... severe neurological disorders, announced today that it has ... with Shire plc to develop AGT-182, an investigational ... both the central nervous system (CNS) and somatic ... MPS II, Hunter syndrome is a rare, severe, ...
(Date:7/23/2014)... 23, 2014 Rolta ... für Sadara Chemical Company (Sadara) erhalten zu ... innerhalb des integrierten Chemiekomplexes von Sadara in ... scope im Wert von mehreren Millionen Dollar ... dar, dessen Wert sich ebenfalls auf mehrere ...
Breaking Medicine Technology:Dompe announces the Food and Drug Administration (FDA) has granted orphan drug designation to its rhNGF-based treatment for neurotrophic keratitis 2Dompe announces the Food and Drug Administration (FDA) has granted orphan drug designation to its rhNGF-based treatment for neurotrophic keratitis 3Dompe announces the Food and Drug Administration (FDA) has granted orphan drug designation to its rhNGF-based treatment for neurotrophic keratitis 4ArmaGen Announces Strategic Licensing and Collaboration Agreement with Shire to Develop AGT-182 for Treatment of Hunter Syndrome 2ArmaGen Announces Strategic Licensing and Collaboration Agreement with Shire to Develop AGT-182 for Treatment of Hunter Syndrome 3Rolta gewinnt Follow-on Award für Engineering Systems für Sadara, Saudi-Arabien im Wert von mehreren Millionen Dollar 2Rolta gewinnt Follow-on Award für Engineering Systems für Sadara, Saudi-Arabien im Wert von mehreren Millionen Dollar 3Rolta gewinnt Follow-on Award für Engineering Systems für Sadara, Saudi-Arabien im Wert von mehreren Millionen Dollar 4
... Ontario, Canada, Oct. 27, 2011 Valeant Pharmaceuticals International, Inc. ... of 8,523,517 additional common shares of Afexa Life Sciences Inc. ... of the offer by its wholly-owned subsidiary 1625907 Alberta Ltd. ... of Afexa. As all of the conditions to the offer ...
... and SYDNEY, Oct. 27, 2011 HeartWare International, Inc. ... innovator of less invasive, miniaturized circulatory support technologies that ... announced revenues of $21.3 million for the third quarter ... increase from $13.8 million in revenues for the same ...
Cached Medicine Technology:Valeant Announces Take-Up of Additional Afexa Shares and Special Meeting of Shareholders of Afexa to Approve Its Privatization 2Valeant Announces Take-Up of Additional Afexa Shares and Special Meeting of Shareholders of Afexa to Approve Its Privatization 3HeartWare International Reports Third Quarter 2011 Revenues of $21.3 Million; 54% Increase From $13.8 Million in Third Quarter 2010 2HeartWare International Reports Third Quarter 2011 Revenues of $21.3 Million; 54% Increase From $13.8 Million in Third Quarter 2010 3HeartWare International Reports Third Quarter 2011 Revenues of $21.3 Million; 54% Increase From $13.8 Million in Third Quarter 2010 4HeartWare International Reports Third Quarter 2011 Revenues of $21.3 Million; 54% Increase From $13.8 Million in Third Quarter 2010 5HeartWare International Reports Third Quarter 2011 Revenues of $21.3 Million; 54% Increase From $13.8 Million in Third Quarter 2010 6
(Date:7/23/2014)... Low enrollment and higher-than-expected administrative ... come up with alternative means to becoming self-sustaining. ... to accomplish this in the July 17 issue ... (HEX). , “We never expected the operating budgets ... Condeluci, an attorney at the law firm Venable ...
(Date:7/23/2014)... DBC Pri-Med LLC , the leading ... more than 260,000 clinicians and the University of South ... national continuing medical education (CME) curriculum to educate and ... ultrasound and how to utilize these technologies at the ... Carolina School of Medicine will deliver its first education ...
(Date:7/23/2014)... TeraGanix has recently announced the ... located only 4.5 miles off of highway I-8. The new ... accessibility for businesses in the Arizona region that use its ... Its Casa Grande location is only 1 hour away from ... from Phoenix. With over 26 million acres of agricultural ...
(Date:7/23/2014)... VA (PRWEB) July 23, 2014 According ... residential real estate transactions throughout the region, the ... trends in June. Homes are selling quickly throughout the ... parts of the region. The Northern Virginia market includes ... Prince William counties. , The Northern Virginia region saw ...
(Date:7/23/2014)... Townsend Security, a leading authority in data ... security solutions now support two factor authentication. This major ... relying on passwords as their only authentication mechanism. , ... Two Factor Authentication software with the following Alliance ... Alliance AES/400 – High performance, NIST validated AES encryption ...
Breaking Medicine News(10 mins):Health News:Industry Observers Tell AIS They Predict Changes to Exchange User Fees, Platforms 2Health News:Industry Observers Tell AIS They Predict Changes to Exchange User Fees, Platforms 3Health News:Pri-Med and the University of South Carolina School of Medicine Launch National Ultrasound Education Initiative for Primary Care Clinicians 2Health News:Pri-Med and the University of South Carolina School of Medicine Launch National Ultrasound Education Initiative for Primary Care Clinicians 3Health News:TeraGanix Opens New Arizona-Based Agricultural Products Supply Facility 2Health News:TeraGanix Opens New Arizona-Based Agricultural Products Supply Facility 3Health News:Northern Virginia Real Estate Company Pasquali Realty Group Announces Median Sale Price Increased in the Region in June 2014 2Health News:Townsend Security Brings Two Factor Authentication to Leading IBM i Security Solutions 2
... April 24 Foundation for,Biomedical Research (FBR) Board Chairman ... the highest civilian honor Congress can,bestow, on Wednesday., ... the world of science,are few, but they are iconic ... said President George W. Bush. "Today we gather to ...
... and Employment,Discrimination, BAYSIDE, N.Y., April 24 ... hailed today,s vote in the,United States Senate ... (GINA), to ban genetic discrimination in,health insurance ... GINA,in April 2007., "TSA has worked ...
... First Patient Receives Cimzia(R) Dose through CIMplicity(TM) within Two ... ... April 24 UCB announced today the launch of its,CIMplicity(TM) ... to severe Crohn,s disease. CIMplicity(TM) provides,Cimzia(R) patients and their caregivers ...
... at Long Beach Veterans Administration Hospital, LONG ... Administration will honor Dr. Richard Merkin, President of,Heritage ... of American,war veterans. The VA, in collaboration with ... research study aimed at,examining diabetic ulcers in veterans. ...
... at 11:00,am, Family Research Council will present a lecture ... Health Policy Studies. Mr.,Moffit will discuss why health care ... applications in medicine, e.g. the,right to choose a pro-life ... the life of a loved one. To have these ...
... of Seniors Act, WASHINGTON, April 24 The ... to preventing,unintentional home injuries, applauds today,s enactment of the ... President Bush yesterday, comes,at a critical time when each ... and about 30 percent of those who fall require ...
Cached Medicine News:Health News:Michael E. DeBakey Receives Congressional Gold Medal 2Health News:Tourette Syndrome Association Applauds the Passage of Genetic Information Nondiscrimination Act 2Health News:UCB Launches CIMplicity(TM) Program to Enhance Treatment Support for Cimzia(R) (certolizumab pegol) Patients and Caregivers 2Health News:UCB Launches CIMplicity(TM) Program to Enhance Treatment Support for Cimzia(R) (certolizumab pegol) Patients and Caregivers 3Health News:UCB Launches CIMplicity(TM) Program to Enhance Treatment Support for Cimzia(R) (certolizumab pegol) Patients and Caregivers 4Health News:UCB Launches CIMplicity(TM) Program to Enhance Treatment Support for Cimzia(R) (certolizumab pegol) Patients and Caregivers 5Health News:UCB Launches CIMplicity(TM) Program to Enhance Treatment Support for Cimzia(R) (certolizumab pegol) Patients and Caregivers 6Health News:UCB Launches CIMplicity(TM) Program to Enhance Treatment Support for Cimzia(R) (certolizumab pegol) Patients and Caregivers 7Health News:Veterans Honor Dr. Richard Merkin During Research Week 2Health News:President Signs Elder Falls Bill Into Law 2
... The Veris physiological monitor offers a comprehensive ... specifically designed for pediatric and neonate patients, ... to 3T. Veris is the first MR ... of pediatric and neonate patient monitoring. The ...
The SonoSite MicroMaxx gives you big machine performance in a lightweight package. This laptop-sized, durable unit represents the technology crossover point between hand-carried ultrasound and larger...
The IDS Gamma-B 25-Hydroxy Vitamin D kit is a conventional liquid phase radioimmunoassay intended for the quantitative determination of 25-hydroxy vitamin D (25-OHD) and other hydroxylated metabolite...
... is a fully automated ... for clotting, photometric and ... tests.The medium-throughput analyser offers ... tubes, 45 reagents onboard, ...
Medicine Products: